Topic · Money
Deals, investment, earnings and who is paying for what. 9 stories from 7 countries.
9 stories
CHSwitzerlandMoney
PolyPeptide shareholders elected a five member board chaired by Samsung Biologics CEO John Rim and removed transfer and voting limits, both effective only at settlement of the CHF 44.31 per share offer.
CNChinaMoney
Gilead agreed to buy PepStar's oral IL-23R peptide program, led by Phase 1 candidate HCXT-2001, for $1.275 billion upfront in cash, with closing expected in Q4 2026.
CNChinaMoney
Hybio forecasts nine month 2026 net profit of RMB 430 million to 450 million, up more than fivefold on peptide active ingredient sales, while a RMB 968 million placement for peptide line expansion expired.
KRSouth KoreaMoney
Samsung Peptide won 87.88% acceptance for its CHF 44.31 per share PolyPeptide offer; approvals, a board vote and settlement are still pending.
ETEthiopiaMoney
Kilitch sells 100% of its Ethiopian cephalosporin unit to an Oromia state enterprise for $14 million, $12.855 million of it to Kilitch, to fund debt cuts and a phased Pen site with GLP-1 plans.
AEUnited Arab EmiratesMoney
Lilly and Mubadala Bio agreed localised packaging and logistics for Lilly GLP-1 medicines, including Mounjaro and Foundayo, at a KEZAD site in Abu Dhabi, rolled out in phases.
ITItalyMoney
Novo bought running filling lines instead of waiting years to build them.
USUnited StatesMoney
Another case of buying a working sterile site rather than building one.
USUnited StatesMoney
A mid-sized contract maker bets heavily that drug companies will keep outsourcing peptide chemistry.
